The effect of the ADP receptor antagonists ATP and adenosine 5’-(β, γ-methylene)triphosphate (AMP-PCP), and the ADP-utilizing enzyme systems creatine phosphokinase/creatine phosphate (CPK/CP) and pyruvate kinase/phosphoenol pyruvate (PK/PEP) on platelet deposition onto type I collagen was examined. An in vitro perfusion system was used, which allowed continuous visualization of the deposition of fluorescently labelled platelets. This system also provided well-controlled rheology, precise quantification of deposition, and allowed the use of heparinized whole human blood (3 u/ml). Heparinization at this level permits the local generation of thrombin near surface platelet aggregates. The contribution of ADP is thus studied with the combined effects of thrombin, thromboxane A2, and other aggregating agents present. Results from these studies indicate that ATP was capable of inhibiting deposition by 60% at 1 pM and 90% at 5 μM (whole blood cone.). AMP-PCP inhibited deposition in a dose dependent manner with a Ki of approximately 80 μM and a maximum inhibition of 60%. Inhibition by CPK/CP was measured at 20, 40, and 60 u/ml, with approximately 45% inhibition achieved for the latter two concentrations. PK/ PEP at 60 u/ml resulted in 70% inhibition. These results support a role for ADP in mediating platelet recruitment in thrombus growth on collagen. Previous work utilizing animal bleeding times supports this conclusion; the present study demonstrates that this role is not dependent upon endothelial or vasoconstrictive effects. Intraplatelet cAMP levels were raised with respect to controls upon exposure to ATP at 8.3 μM (p <0.025), and 15 μM (p <0.005), as well as AMP-PCP at 42-500 μM (p <0.005). Since increasing intraplatelet cAMP may affect platelet function, these results raise another possible interpretation for some of our platelet deposition data as well as that of previous experimenters. However, since ATP at 1 μM was not shown to affect intraplatelet cAMP, it is believed that at least part of the ATP-mediated inhibition was due to ADP receptor competition.
References
1
Haslam RJ.
Role of adenosine diphosphate in the aggregation of human blood platelets by thrombin and by fatty acids. Nature 1964; 202: 765-768
2
Haslam RJ.
Mechanisms of blood platelet aggregation. In: Physiology of Hemostasis and Thrombosis.
Johnson SA,
Seegers WH.
(eds) Charles C Thomas; Springfield, IL: 1967. pp 88-112
3
Mills DCB,
Robb IA,
Roberts GCK.
The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J Physiol (London) 1968; 195: 715-729
7
Emms H,
Lewis GP.
The roles of prostaglandin endoperoxides, thromboxane A2, and adenosine diphosphate in collagen-induced aggregation in man and the rat. Br J Pharmacol 1986; 87: 109-115
13
Macfarlane DE,
Mills DCB.
The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood 1975; 46: 309-320
14
Grabowski EF,
Franta JT,
Didisheim P.
Platelet aggregation in flowing blood in vitro. II. Dependence of aggregate growth rate on ADP concentration and shear rate. Microvasc Res 1978; 16: 183-195
15
Zawilska KM,
Born GVR,
Begent NA.
Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits. Br J Haematol 1982; 50: 317-325
18
Haslam RJ,
Cusack NJ.
Blood platelet receptors for ADP and for adenosine. In: Purinergic Receptors: Receptors and Recognition, Series B.
Burnstock G.
(ed). Vol 12 Chapman and Hall; London: 1981. pp 221-285
19
Cusack NJ,
Hourani SMO.
Adenosine 5’-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol 1982; 76: 221-227
25
Puri PN,
Zhou F,
Colman RW.
Cleavage of a 100 kDa membrane protein (aggregin) during thrombin-induced platelet aggregation is mediated by the high affinity thrombin receptors. Biochem Biophys Res Commun 1989; 162: 1017-1024
28
Wagner WR,
Hubbell JA.
Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood. J Lab Clin Med 1990; 116: 636-650
31
Hauptmann J,
Kaiser B,
Nowak G,
Sturzebecher J,
Markwardt F.
Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemostas 1990; 63: 220-223
32
Desai NP,
Hubbell JA.
The short-term blood biocompatibility of poly(hydroxyethyl methacrylate-co-methyl methacrylate) in an in vitro flow system measured by digital videomicroscopy. J Biomater Sci Polymer Edn 1989; 1: 123-146
34
Cazenave JP,
Packham MA,
Mustard JF.
Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med 1973; 82: 978-990
39
Nunn B,
Chamberlain PD.
Further evidence against the validity of using an ADP-removing enzyme system (CP/CPK) for demonstrating the role of secreted ADP in platelet activation. Thromb Res 1983; 30: 19-26
40
Gaarder A,
Jonsen J,
Laland S,
Hellem A,
Owren PA.
Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
41
Bom GVR,
Kratzer MAA.
Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol (London) 1984; 354: 419-429
43
Bell DN,
Spain S,
Goldsmith HL.
The effect of red blood cells on the ADP-induced aggregation of human platelets in flow through tubes. Thromb Haemostas 1990; 63: 112-121
47
Wagner WR,
Hubbell JA.
Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen. J Lab Clin Med. (in press)
